Natera Oncology’s Post

Dr. Nelson Dusetti: Transforming Pancreatic Cancer Treatment in 2024 In 2024, Dr. Nelson Dusetti, a leading researcher at the Cancer Research Center of Marseille (CRCM), achieved significant milestones in advancing personalized care for pancreatic cancer patients. This year, Dr. Dusetti presented the Pancreas-View molecular signature test at the American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing its ability to predict individual patient responses to chemotherapy. This innovation allows for personalized treatment plans, improving survival rates and minimizing toxicity. Dr. Dusetti also integrated artificial intelligence (AI) into oncology by utilizing AI-assisted transcriptomic signatures to address tumor heterogeneity in pancreatic ductal adenocarcinoma (PDAC). These tools help identify the most effective and least toxic chemotherapy options for patients, marking a critical step forward in precision oncology. Expanding the reach of personalized medicine, his team developed techniques to apply transcriptomic signatures to metastatic pancreatic cancer patients, using fine needle aspiration (FNA) biopsies to predict treatment sensitivity. Dr. Dusetti’s work in 2024 exemplifies the potential of precision medicine to transform outcomes for pancreatic cancer patients, offering hope through innovation and targeted care. #NelsonDusetti #PancreaticCancer #ASCO2024 #PrecisionMedicine #OncologyResearch #CancerCareInnovation

💡 Insightful and short talk for anyone focused on Breast Cancer research, especially relating to ADCs. The speaker and panelists discussed: - How physicians are grappling with optimal ADC sequencing given shorter PFS for the second ADC vs the first ADC and limited available data to inform decision making - Factors that influence sequencing (direct vs sandwiching) - biomarker status, tolerability - AEs and their grade + management, burden and pace of disease, and dosing schedule Thanks Nathan Hubbard for sharing. https://lnkd.in/eX2Utawx

I am pleased to announce the publication of our recent research in PLOS ONE, titled: "Targeting necroptosis in MCF-7 breast cancer cells: In Silico insights into 8,12-dimethoxysanguinarine from Eomecon Chionantha through molecular docking, dynamics, DFT, and MEP studies." This study highlights the potential of 8,12-dimethoxysanguinarine as a novel agent targeting necroptosis in breast cancer cells, employing advanced computational methods to provide detailed molecular insights. I extend my gratitude to all those who supported and guided this work. The full article is available here: https://lnkd.in/eyr6S-k8 #Research #CancerTherapy #DrugDiscovery #InSilico #PLOSOne #ScientificPublication

Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial https://lnkd.in/enHyvT4t

Antibody-drug conjugate datopotamab deruxtecan shows promising activity and a manageable safety profile in patients with advanced breast cancer, according to a study led by our Dr. Funda Meric-Bernstam. Read about this and more research from MD Anderson. #CancerResearch #EndCancer

Excited to announce the publication of our latest review article, "Phage Display Screening in Breast Cancer: From Peptide Discovery to Clinical Applications", in the prestigious Life Science journal! This comprehensive review dives deep into the promising field of phage display technology and its potential in discovering novel peptides that target breast cancer. As breast cancer continues to be a major global health challenge, the insights provided in this review offer a roadmap for the future of targeted therapies, paving the way from peptide discovery to clinical applications. The article is available for free access on ScienceDirect for the next 50 days. Be sure to read or download it using the link below and stay informed about the latest advancements in breast cancer research! Link: https://lnkd.in/gzjQiB8x A big thank you to my amazing students (Ashlyn Y. and Sylvester Chu Yee Chun) and colleagues (A/P Dr Adeline Chia, A/P Dr Yap Wei Hsum and Dr. Chuan Loo Wong) for their incredible efforts and teamwork to finally get this important piece of work published. Your dedication has made this possible! #Research #BreastCancer #PhageDisplay #PeptideDiscovery #TargetedTherapies #LifeScience #ScienceDirect #CancerResearch

🌟 Reminder: Dr. Josep Tabernero MD, PhD Tabernero's Insights at ESMO 2024 🌟 As we reflect on the highlights from #ESMO2024, this is a reminder of the impactful presentations and discussions led by Dr. Josep Tabernero MD, PhD , a prominent figure in oncology research. Dr. Tabernero played a key role at the conference, including: Chairing an Industry Satellite Symposium on precision oncology for BRAF-mutant cancers, held on September 16, 2024. The session explored the latest strategies for managing BRAFV600 mutations in solid tumors, including melanoma, colorectal cancer, and non-small cell lung cancer, with an expert panel sharing insights on targeting these mutations for optimal patient outcomes. Presenting data from the BREAKWATER study, which evaluated the combination of encorafenib and cetuximab with chemotherapy in BRAF V600E-mutant metastatic colorectal cancer. The study showcased promising improvements in efficacy and safety, advancing the potential treatment options for this challenging cancer type. Dr. Josep Tabernero MD, PhD’s contributions at ESMO continue to drive progress in targeted cancer therapies and precision medicine, providing hope for patients with hard-to-treat cancers. For more details, check out the full presentation and updates: https://lnkd.in/e2xXwUiq Stay tuned for more updates and reflections on #ESMO2024. #Oncology #CancerResearch #PrecisionOncology #TargetedTherapies #ColorectalCancer #BRAFMutations #JosepTabernero #BREAKWATERStudy

Dr. Pashtoon Kasi, a leading figure in gastrointestinal oncology, has recently made significant strides in advancing the treatment of colorectal cancer. One of his most impactful contributions is his work on the NEST-1 clinical trial, which explored the use of botensilimab and balstilimab for patients with microsatellite stable (MSS) colorectal cancer—a subtype traditionally resistant to immunotherapy. The trial delivered remarkable results, showcasing unprecedented tumor reductions. This breakthrough opens new avenues for treating MSS colorectal cancer, a condition that has long posed challenges for oncologists. Dr. Kasi’s expertise also extends to the application of liquid biopsies using circulating tumor DNA (ctDNA). This cutting-edge approach enables real-time monitoring of cancer progression and provides valuable insights into tumor dynamics, paving the way for more personalized and precise treatments. With over #150 peer-reviewed publications, Dr. Kasi continues to push the boundaries of oncology, combining innovative research with a patient-centered approach. His work is transforming cancer care and improving outcomes for patients worldwide. #Oncology #ColorectalCancer #PashtoonKasi #ClinicalTrials #LiquidBiopsy #CancerResearch #MediaMedic #Immunotherapy #PrecisionMedicine

💥A week full of great news in the field of oncology ‼️🚨 1- Breast Cancer: ▫️Early-stage TNBC treated with locoregional therapy only, higher TIL levels in breast cancer tissue were associated with improved survival. Will TIL’s be a biomarker for chemo de-escalation in some TNBC ? ▫️SENOMAC trial: Validation of omission of completion of ALND in patients with clinically node-negative and sentinel-node macrometastasis, and replace with radiation therapy to the axilla 2- Locally- advanced badder cancer: ▫️Updated results of Check-Mate 274 (presented yesterday in EAU-2024): OS benefit in the ITT population and especially in the PDL-1 + subgroup, (HR: 0.5 !!) reinforcing adjuvant nivo for high risk BC (no neo adj treatment, T3/T4, N+) Adjuvant IO for all in the future ? How to identify patients cured without adjuvant IO ? —> Biomarker- guided startegy ? 3- Limited stage small-cell lung cancer: ▫️ADRIATIC trial: OS benefit with durvalumab +/- tremelimumab in LS- SCLC after chemo-radiation 4- The big agnostic FDA approval of trastuzumab- Deruxtecan in HER-2 positive unresectable/ metastatic solid tumors !! #oncology #agnostic #approvals #advances #Newtherapies

U.S. clinical validation data alert 🚀 🇺🇸 At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting this week, the leading US cancer center Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute will present the first clinical validation of Histotype Px® Colorectal in a U.S. colon cancer patient cohort. The ASCO Annual Meeting is the world’s largest oncology conference and the findings are an important step towards clinical implementation in the US as a decision tool to guide adjuvant chemotherapy (ACT) decisions. This analysis of 159 patients with stage 2 and stage 3 colon cancer at Ohio State University Comprehensive Cancer Center (2016-2020) shows the promising potential of the Histotype Px Colorectal biomarker to predict patient outcomes and support better treatment decisions in stage II-III colon cancer patients in a U.S. cohort. 🔍 Key Findings: • Histotype Px Colorectal, an AI-based biomarker, effectively risk stratifies patients into low, intermediate, and high-risk groups. • The biomarker showed significant ability to predict both cancer-specific survival and time-to-recurrence. • For high vs. low-risk patients, it predicted cancer-specific survival (HR=7.80, p<0.001) and time-to-recurrence (HR=7.59, p<0.001). 💡 Impact: • The findings highlight the potential utility of this innovative biomarker and how it could optimize how we determine the necessity and intensity of ACT. • This is particularly important given the current controversy and limited benefits for many patients undergoing ACT. 🌟 Looking Ahead: • This is an important step towards personalized treatment strategies, improving outcomes and quality of life for colon cancer patients. • These promising results pave the way for larger, more diverse studies to confirm the biomarker’s utility. In the coming months Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute will further expand the sample of patients to provide additional support for the clinical utility of Histotype Px Colorectal. Congratulations to the team and everyone involved in this important research. Stay tuned for more updates and future studies with our partners! #CancerResearch #Oncology #AIinHealthcare #PrecisionMedicine #ColorectalCancer #ASCO #ASCO2024 #DoMore Full Press Release can be found here: https://lnkd.in/d8S5Rn86 Link to Full Abstract: https://lnkd.in/dxWwsmGQ   Live poster session: Hall A, Abstract 3622, Poster Board 285 @ 1 June 2024, 1:30 PM-4:30 PM CDT Eric Miller Giovanni Lujan MD Vidya Arole Jessica Maupin Sandra Boutros Anne Noonan Sepp De Raedt The Ohio State University Wexner Medical Center